A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Institut Paoli-Calmettes; Oncologie Medicale 1, Marseille

Centre Francois Baclesse; Oncologie, Caen

Centre Georges François Leclerc, Dijon

Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid

Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid

Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid

Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse

Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo

Institut Bergonie; Oncologie, Bordeaux

Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca

Vanderbilt, Nashville

Centre Rene Gauducheau, Saint-Herblain

Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia

Karmanos Cancer Institute, Detroit

Klinik der Uni zu Koeln; Klinik I für Innere Medizin; Onkologie, Cologne

Washington University, St Louis

Universitätsklinikum Mannheim, Tagestherapiezentrum, Interdisziplinäres Tumorzentrum, Mannheim

Centre Leon Berard; Departement Oncologie Medicale, Lyon

University of Texas M.D. Anderson Cancer Center, Houston

Rocky Mountain Cancer Centers, LLP, Aurora

Arizona Oncology, Tucson

Institut Gustave Roussy; Sitep, Villejuif

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

Tianjin Cancer Hospital, Tianjin

Massachusetts General Hospital;Oncology, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Memorial Sloan-Kettering Cancer Center, New York

Hospital del Mar; Servicio de Oncologia, Barcelona

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

Aberdeen Royal Infirmary, Aberdeen

The Royal Marsden Hospital; Dept of Medicine, London

The Royal Marsden Hospital, Sutton